DE60029953D1 - Spezifische antikörper gegen humanes choriongonadotropin hormone und deren verwendung in therapie und diagnose - Google Patents

Spezifische antikörper gegen humanes choriongonadotropin hormone und deren verwendung in therapie und diagnose

Info

Publication number
DE60029953D1
DE60029953D1 DE60029953T DE60029953T DE60029953D1 DE 60029953 D1 DE60029953 D1 DE 60029953D1 DE 60029953 T DE60029953 T DE 60029953T DE 60029953 T DE60029953 T DE 60029953T DE 60029953 D1 DE60029953 D1 DE 60029953D1
Authority
DE
Germany
Prior art keywords
hcg
hormone
diagnosis
therapy
specific antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60029953T
Other languages
English (en)
Other versions
DE60029953T2 (de
Inventor
L Iversen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sarepta Therapeutics Inc
Original Assignee
AVI Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AVI Biopharma Inc filed Critical AVI Biopharma Inc
Publication of DE60029953D1 publication Critical patent/DE60029953D1/de
Application granted granted Critical
Publication of DE60029953T2 publication Critical patent/DE60029953T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
DE60029953T 1999-05-17 2000-05-15 Spezifische Antikörper gegen humanes Choriongonadotropin und deren Verwendung in Therapie und Diagnose Expired - Fee Related DE60029953T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US13441999P 1999-05-17 1999-05-17
US13443299P 1999-05-17 1999-05-17
US134432P 1999-05-17
US134419P 1999-05-17
PCT/US2000/013392 WO2000069915A2 (en) 1999-05-17 2000-05-15 COMBINED APPROACH TO TREATMENT OF CANCER WITH hCG VACCINES

Publications (2)

Publication Number Publication Date
DE60029953D1 true DE60029953D1 (de) 2006-09-21
DE60029953T2 DE60029953T2 (de) 2007-09-13

Family

ID=26832312

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60029953T Expired - Fee Related DE60029953T2 (de) 1999-05-17 2000-05-15 Spezifische Antikörper gegen humanes Choriongonadotropin und deren Verwendung in Therapie und Diagnose

Country Status (10)

Country Link
US (1) US6764680B2 (de)
EP (1) EP1183275B1 (de)
JP (1) JP2003502025A (de)
KR (1) KR100684573B1 (de)
AT (1) ATE335764T1 (de)
AU (1) AU5136100A (de)
CA (1) CA2369397A1 (de)
DE (1) DE60029953T2 (de)
ES (1) ES2269150T3 (de)
WO (1) WO2000069915A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294171B2 (en) * 1999-09-14 2001-09-25 Milkhaus Laboratory, Inc. Methods for treating disease states comprising administration of low levels of antibodies
US8128922B2 (en) * 1999-10-20 2012-03-06 Johns Hopkins University Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
EP1644048B1 (de) 2003-05-05 2015-04-29 Johns Hopkins University Anti-krebs-dna-vakzine mit einer für plasmide kodierenden signalsequenz, mutiertes onkoprotein-antigen und hitzeschockprotein
WO2005005465A2 (en) * 2003-07-08 2005-01-20 Board Of Regents, University Of Texas System Methods and compositions to enhance immune responses via recall antigens
US20080254445A1 (en) * 2003-09-22 2008-10-16 Kyogo Itoh Prognosis in Cancer Patients Vaccinated with a Cancer Antigen Peptide-Associated Agent
CA2505329C (en) * 2004-04-26 2013-01-22 General Mills Ip Holdings Ii, Llc Low sugar presweetened dry coated cereals and method of preparation
WO2005117915A1 (en) * 2004-06-03 2005-12-15 F. Hoffmann-La Roche Ag Treatment with oxaliplatin and an egfr-inhibitor
MXPA06014769A (es) * 2004-06-17 2007-03-26 Mannkind Corp Eficiencia mejorada de la inmunoterapia al integrar metodos de diagnostico con terapeuticos.
JP2006248978A (ja) 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
US8642330B2 (en) * 2005-08-08 2014-02-04 Onconon, Llc Antibody compositions, methods for treating neoplastic disease and methods for regulating fertility
AR059922A1 (es) * 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
CN101314619B (zh) * 2007-06-01 2010-12-22 齐鲁制药有限公司 肿瘤治疗性疫苗ctp37crm197免疫原及其制备方法与应用
EP2252285B1 (de) * 2008-01-18 2015-04-15 Horphag Research Ip (Mir) Ltd. Behandlung vom nicht-normalen intraocularen druck

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4691006A (en) 1983-03-04 1987-09-01 Ohio State University Antigenic modification of polypeptides
WO1984004598A1 (en) * 1983-05-06 1984-11-22 Univ Columbia Immunoassay for human chorionic gonadotropin
US6319504B1 (en) * 1996-06-24 2001-11-20 University Of Maryland Biotechnology Institute Treatment and prevention of HIV infection by administration of derivatives of human chorionic gonadotropin

Also Published As

Publication number Publication date
US6764680B2 (en) 2004-07-20
ES2269150T3 (es) 2007-04-01
KR20020007416A (ko) 2002-01-26
US20020164338A1 (en) 2002-11-07
DE60029953T2 (de) 2007-09-13
EP1183275A2 (de) 2002-03-06
ATE335764T1 (de) 2006-09-15
JP2003502025A (ja) 2003-01-21
AU5136100A (en) 2000-12-05
WO2000069915A2 (en) 2000-11-23
CA2369397A1 (en) 2000-11-23
KR100684573B1 (ko) 2007-02-20
EP1183275B1 (de) 2006-08-09
WO2000069915A3 (en) 2001-07-26

Similar Documents

Publication Publication Date Title
DE60029953D1 (de) Spezifische antikörper gegen humanes choriongonadotropin hormone und deren verwendung in therapie und diagnose
DE3750389D1 (de) Antikörper gegen menschlichen progesteronrezeptor sowie diagnosematerial und -verfahren.
DE69028388D1 (de) Monoklonaler antikörper gegen ein neues humanes tumor assoziiertes antigen
PT744958E (pt) Bancos de anticorpos policlonais
IL142948A0 (en) Agents and compositions and methods utilizing same useful in diagnosing and/or treating or preventing plaque forming diseases
LU91556I2 (fr) Anticorps humains reconstitués dirigés contre un récepteur de l'interleukine 6 humaine - TOCILIZUMAB
TR199801722T2 (xx) Peptit imm�nojenler.
ATE442439T1 (de) Melanoma antigene p15 und deren anwendung in diagnostischen und therapeutischen verfahren
AR033832A1 (es) Un metodo ex vivo para diagnosticar una enfermedad autoinmune, anticuerpo, composicion de diagnostico que lo comprende, y usos del anticuerpo
BR9106303A (pt) Imonogeno humano composicao,celula de mamifero,peptido,vacina contra sintomas de esclerose multipla,metodo para tratar ou prevenir doenca com sintomas de esclerose multipla e conjunto para diagnosticar esclerose multipla
DE69333076D1 (de) Test und behandlung von demyelinierenden krankheiten wie multiple sklerosis
FI900230A0 (fi) Anti-idiotypa antikroppar mot antikroppar mot antigener med hoeg molekylvikt associerade till human melanoma.
WO1994005329A1 (en) Stimulation of an antitumor t-cell response using anti-idiotypic antibodies
WO2003012395A3 (en) Early detection of mycobacterial disease using peptides
EP2193804A3 (de) Rekombinantes Adenylat-Cyclase-Toxin von Bordetella induziert T-Zell-Antworten gegen tumorale Antigene
Stremple et al. Antibodies to synthetic human gastrin I
Butler et al. Effect of physical state and route of inoculation of diphtheria toxoid on the formation of nasal secretory and serum antibodies in man
ATE137674T1 (de) Von mca 16-88 erkanntes antigen
ATE138200T1 (de) Das von mca-28a32 erkannte antigen
GB2314334A (en) Improved production of antibodies through the use of antigen antibody complexes
Roy et al. ABA-specific responses are I region restricted by the carriers used for immunization.
Lieberman et al. Production of antibody in the canine tracheal pouch after local and systemic influenza immunization
Starzyńska et al. The immunological consequences of insulin therapy
Lucchese et al. protEomic pEptidE scan of porphyromonas gingiValis fima typE ii for sEarching potEntial b-cEll EpitopEs
NO924803L (no) Tumor-relatert monoklonalt antistoff 88bv59

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee